Can Helicobacter pylori-associated gastritis reduce vitamin B12 availability?

Helicobacter pylori–associated gastritis is a clinically plausible contributor to reduced vitamin B12 availability, especially when inflammation or atrophy affects the gastric corpus and parietal-cell function.

Clinical evidence

• Gastric processing is essential for dietary B12 absorption: acid and pepsin release cobalamin from food proteins, then intrinsic factor permits uptake in the terminal ileum. Disruption of these steps can reduce bioavailable B12.
• Observational evidence links H. pylori infection with lower circulating B12 concentrations. A systematic review/meta-analysis found lower B12 in infected versus uninfected individuals and increases after successful eradication, although responses after eradication were highly heterogeneous.
• In a before–after cohort of older B12-deficient patients, eradication was followed by increased B12 and reduced homocysteine, consistent with improved functional B12 status.

Mechanistic interpretation

• Corpus-predominant H. pylori inflammation or atrophic change can plausibly impair parietal-cell-dependent acid secretion and pepsin-mediated liberation of food-bound B12.
• The acid/pepsin-to-B12 pathway is well established. In contrast, direct impairment of intrinsic-factor production or function specifically from H. pylori gastritis remains a proposed mechanism rather than one directly demonstrated alongside impaired dietary B12 absorption in human studies.

Clinical implications

• B12 assessment is particularly relevant in corpus-predominant atrophic gastritis. In confirmed atrophic gastritis, guidance supports testing for H. pylori and treating infection.
• Low B12 should not automatically be attributed to H. pylori, since diet, medications, autoimmune gastritis, and other causes may contribute.

Bottom line

• H. pylori gastritis can plausibly reduce B12 availability through disrupted gastric processing, and clinical association data support relevance; however, the full acid–pepsin–intrinsic-factor pathway has not been definitively demonstrated in individual patients.